Ou Yamaguchi

2.5k total citations
88 papers, 1.1k citations indexed

About

Ou Yamaguchi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Ou Yamaguchi has authored 88 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Oncology, 60 papers in Pulmonary and Respiratory Medicine and 13 papers in Epidemiology. Recurrent topics in Ou Yamaguchi's work include Lung Cancer Treatments and Mutations (50 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Lung Cancer Research Studies (23 papers). Ou Yamaguchi is often cited by papers focused on Lung Cancer Treatments and Mutations (50 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Lung Cancer Research Studies (23 papers). Ou Yamaguchi collaborates with scholars based in Japan, United States and Australia. Ou Yamaguchi's co-authors include Hiroshi Kagamu, Kyoichi Kaira, Kunihiko Kobayashi, Ayako Shiono, Yu Miura, Atsuto Mouri, Kosuke Hashimoto, Yoshitake Murayama, Fuyumi Nishihara and Hisao Imai and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Ou Yamaguchi

79 papers receiving 1.1k citations

Peers

Ou Yamaguchi
Shunsuke Teraoka Japan
Yukihiro Toi Japan
Ayako Shiono Japan
Masahiro Morise Japan
Aurélien Gobert France
Hidenobu Ishii Japan
Takaaki Tokito Japan
Gongyan Chen China
Yu Miura Japan
Alexandros Xyrafas Switzerland
Shunsuke Teraoka Japan
Ou Yamaguchi
Citations per year, relative to Ou Yamaguchi Ou Yamaguchi (= 1×) peers Shunsuke Teraoka

Countries citing papers authored by Ou Yamaguchi

Since Specialization
Citations

This map shows the geographic impact of Ou Yamaguchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ou Yamaguchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ou Yamaguchi more than expected).

Fields of papers citing papers by Ou Yamaguchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ou Yamaguchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ou Yamaguchi. The network helps show where Ou Yamaguchi may publish in the future.

Co-authorship network of co-authors of Ou Yamaguchi

This figure shows the co-authorship network connecting the top 25 collaborators of Ou Yamaguchi. A scholar is included among the top collaborators of Ou Yamaguchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ou Yamaguchi. Ou Yamaguchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Uchida, Takahiro, Kazuyuki Nakagome, Kosuke Hashimoto, et al.. (2025). Eosinophils as predictive biomarkers in anti-programmed cell death 1 monotherapy for non-small cell lung cancer. Frontiers in Immunology. 16. 1574314–1574314. 1 indexed citations
2.
Imai, Hisao, Ayako Shiono, Kosuke Hashimoto, et al.. (2025). Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer. Anticancer Research. 45(2). 733–741. 1 indexed citations
3.
Endo, Satoshi, Hisao Imai, Atsuto Mouri, et al.. (2025). Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 151(1). 43–43. 2 indexed citations
4.
Kaira, Kyoichi, Hisao Imai, Ayako Shiono, et al.. (2025). Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy. Translational Lung Cancer Research. 14(5). 1569–1581. 1 indexed citations
5.
Ito, Koki, Kyoichi Kaira, Ou Yamaguchi, et al.. (2024). Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy. Oncology Letters. 27(3). 110–110. 4 indexed citations
6.
Hashimoto, Kosuke, Kyoichi Kaira, Hisao Imai, et al.. (2024). Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer. Cancer Imaging. 24(1). 157–157. 1 indexed citations
7.
8.
9.
Yamaguchi, Ou, Norimitsu Kasahara, Hiroshi Soda, et al.. (2023). Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. Scientific Reports. 13(1). 20848–20848. 5 indexed citations
10.
Kaira, Kyoichi, Hisao Imai, Atsuto Mouri, et al.. (2023). Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib. Thoracic Cancer. 14(29). 2950–2961. 3 indexed citations
11.
12.
Kagamu, Hiroshi, Shigehisa Kitano, Ou Yamaguchi, et al.. (2022). Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy. Cancer Research. 82(24). 4641–4653. 27 indexed citations
13.
Mouri, Atsuto, Kyoichi Kaira, Ou Yamaguchi, et al.. (2021). Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. Frontiers in Oncology. 11. 610952–610952. 11 indexed citations
14.
Kaira, Kyoichi, et al.. (2020). Osimertinib induced cardiomyopathy. Medicine. 99(39). e22301–e22301. 13 indexed citations
15.
Yamaguchi, Ou, Kyoichi Kaira, Kosuke Hashimoto, et al.. (2020). Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%. Scientific Reports. 10(1). 14990–14990. 24 indexed citations
16.
Yamaguchi, Ou, Hisao Imai, Hiroyuki Minemura, et al.. (2020). Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 85(4). 761–771. 39 indexed citations
17.
Kagamu, Hiroshi, Shigehisa Kitano, Ou Yamaguchi, et al.. (2019). CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. Cancer Immunology Research. 8(3). 334–344. 169 indexed citations
18.
Imai, Hisao, Ou Yamaguchi, Kensuke Suzuki, et al.. (2019). P1.04-34 Efficacy and Safety of First-Line Pembrolizumab Monotherapy in Elderly Patients (Aged ≥ 75 years) with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S453–S453.
19.
Yamaguchi, Ou, Kyoichi Kaira, Atsuto Mouri, et al.. (2019). Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. Cancer Chemotherapy and Pharmacology. 83(5). 817–825. 12 indexed citations
20.
Kobayashi, Masanori, Ou Yamaguchi, Koji Nagata, Kouichi Nonaka, & Shomei Ryozawa. (2017). Acute hemorrhagic gastritis after nivolumab treatment. Gastrointestinal Endoscopy. 86(5). 915–916. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shunsuke Teraoka Breakdown of academic impact, for papers by Yukihiro Toi Breakdown of academic impact, for papers by Ayako Shiono Breakdown of academic impact, for papers by Masahiro Morise Breakdown of academic impact, for papers by Aurélien Gobert Breakdown of academic impact, for papers by Hidenobu Ishii Breakdown of academic impact, for papers by Takaaki Tokito Breakdown of academic impact, for papers by Gongyan Chen Breakdown of academic impact, for papers by Yu Miura Breakdown of academic impact, for papers by Alexandros Xyrafas
Rankless by CCL
2026